Prosight Management, LP Uro Gen Pharma Ltd. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$16.5 - $29.7 $2.41 Million - $4.34 Million	-146,179 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $978,215 - $2.47 Million	-71,507 Reduced 32.85%	146,179 $2.61 Million
Q4 2019 Feb 14, 2020	SELL	$21.11 - $34.86 $2.27 Million - $3.75 Million	-107,699 Reduced 33.1%	217,686 $7.26 Million
Q3 2019 Nov 14, 2019	BUY	$23.83 - $36.44 $1.54 Million - $2.35 Million	64,457 Added 24.7%	325,385 $7.75 Million
Q2 2019 Aug 14, 2019	BUY	$32.75 - $40.35 $3.38 Million - $4.16 Million	103,066 Added 65.29%	260,928 $9.38 Million
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $5.6 Million - $8.61 Million	157,862 New	157,862 $5.83 Million

120

39.3M

158K

161K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $282M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.